Complications of levodopa therapy in Parkinson’s disease

References

• Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin. 1996;14:317–335.
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Basic research on dopamine in Parkinson’s disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener Dis. 2008;5:114–117.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stern MB, Sethi K. Scientific and clinical basis for the treatment of PD – 2009. Neurology. 2009;72(21 Suppl 4):S1–136.
   PubMed Web of Science ®Google Scholar
• Mouradian MM, Heuser IJ, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson’s disease. Ann Neurol. 1989;25(5):523–526.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine receptor stimulation in the treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677–687.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Gracies J-M, Goetz CC, et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson’s disease: a double-blind video-based analysis. Mov Disord. 2009;24:336–343.
   PubMed Web of Science ®Google Scholar
• Goulet M, Morissette M, Calon F, et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience. 1997;79:497–507.
   PubMed Web of Science ®Google Scholar
• Pearce RK, Banerji T, Jenner P, et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmose. Mov Disord. 1998;13:234–241.
   PubMed Web of Science ®Google Scholar
• Stockwell KA, Scheller D, Rose S, et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol. 2009;219:533–542.
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levopdopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–458.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease. A randomized controlled trial. JAMA. 2000;284:1931–1938.
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a 4-year randomized, controlled trial. Arch Neurol. 2004;61:1044–1053.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–1491.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28:1064–1071.
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, et al. Impact of motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20(2):224–230.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID study). A randomized clinical trial. JAMA Neurol. 2017;74:941–949.
   PubMed Web of Science ®Google Scholar
• Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord J. 2017;32:1701–1709.
   PubMed Web of Science ®Google Scholar
• Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson’s disease: a randomized controlled trial. JAMA. 2009;301:63–73.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355:896–908.
   Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajenjunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomized, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–149.
   PubMed Web of Science ®Google Scholar
• Antonini A, Fung V, Boyd J. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov Disord J. 2016;31:530–537.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT02799381?term=duodopa&draw=2&rank=17
   Google Scholar
• Rajput AH, Martin W, Saint-Hilaire MH. Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multi-center trial. Neurology. 1997;49:1066–1071.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol. 1997;42:747–755.
   PubMed Web of Science ®Google Scholar
• Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson’s disease and motor fluctuations. A randomized clinical trial. JAMA Neurol. 2017;74:197–206.
   PubMed Web of Science ®Google Scholar
• Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426–432.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. Arch Neurol. 2005;62:241–248.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomized, double-blind, parallel-group trial. Lancet. 2005;365:947–954.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson’s disease and motor fluctuations. A randomized clinical trial. JAMA Neurol. 2017;74:216–224.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release. Randomized, controlled study in advanced Parkinson’s disease. Neurology. 2007;68:1108–1115.
   PubMed Web of Science ®Google Scholar
• Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–168.
   PubMed Web of Science ®Google Scholar
• Dewey RB, Hutton T, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385–1392.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007;258:137–143.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Poewe W, Roscal O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicenter, double-blind, randomized, placebo-controlled trial. Lancet Neurol. 2018;17:749–759.
   PubMed Web of Science ®Google Scholar
• LeWitt P, Friedman H, Giladi N. Sustained release carbidopa-levodopa (accordion pill) in patients with advanced Parkinson’s disease: pharmacokinetic and clinical experience. Mov Disord. 2013;28(Suppl 1):S499.
   Google Scholar
• Hauser RA, Stocchi F, Rascol O, et al. Preladenant as an adjunctive therapy with levodopa in Parkinson’s disease. Two randomized clinical trials and lessons learned. JAMA Neurol. 2015;72:1491–1500.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Shulman LM, Trugman JM. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177–2185.
   PubMed Web of Science ®Google Scholar
• Pourcher E, Fernandez HF, Stacy M, et al. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Related Disord. 2012;18:178–184.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord. 2010;25:1437–1443.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T. The Japanese istradefylline study group. Adenosine A2a antagonist reduces daily OFF time in Parkinson’s disease. Mov Disord. 2013;28:1138–1141.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stocchi F, Poewe W, et al. Safety, efficacy and tolerability of continuous SC LC/CD (ND0612) infusion in PD patients with motor fluctuations. Presented at the International Congress on Parkinson’s Disease and Movement Disorders; 2017 June 4–8; Vancouver, BC.
   Google Scholar
• Stocchi F, Torti M, Vacca L, et al. A phase 2a study of standard administration versus continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease. Presented at the International Congress on Parkinson’s Disease and Movement Disorders; 2016 June 19–23; Berlin, Germany.
   Google Scholar
• Voyager therapeutics Parkinson’s trial shows positive results; 2018. Available from: https://www.biospace.com/article/voyager-therapeutic-s-parkinson-s-trial-shows-positive-results/
   Google Scholar
• CVT-301 phase 3 data showed significantly improved motor function during OFF periods in Parkinson’s disease; 2017. Available from: http://ir.acorda.com/investors/investor-news/investor-news-details/2017/CVT-301-Phase-3-Data-Showed-Significantly-Improved-Motor-Function-During-OFF-Periods-in-Parkinsons-Disease/default.aspx
   Google Scholar
• Sunovion announces positive topline results from pivotal study of apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease; 2018. Available from: https://news.sunovion.com/press-release/sunovion-announces-positive-topline-results-pivotal-study-apomorphine-sublingual-film)
   Google Scholar
• Stalevo® USPI
   Google Scholar
• Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates. Mov Disord J. 2005;20:306–314.
   PubMed Web of Science ®Google Scholar
• Parkinson’s Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–2508.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH. Punding on l-dopa. Mov Disord. 1999;14:836–838.
   PubMed Web of Science ®Google Scholar
• Evans A, Katzenshlager R, Paviour D, et al. Punding in Parkinson’s disease. Its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19:397–405.
   PubMed Web of Science ®Google Scholar
• Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry. Lanced Neurol. 2003;2:595–604.
   PubMed Web of Science ®Google Scholar
• Evans AH, Lawrence AD, Potts J et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson’s disease. Neurology. 2005;65:1570–1574.
   PubMed Web of Science ®Google Scholar